incubated with 20 ml Sepharose-immobilized monoclonal anti-HA antibodies (Covance). Beads were washed with buffer T without BSA before elution. DSP-induced crosslinks in eluted proteins were thiol-cleaved before separation by 8-16% SDS-PAGE and detection by Sypro Ruby (Bio-Rad).
Cryptosporidium species cause acute gastroenteritis and diarrhoea worldwide. They are members of the Apicomplexa-protozoan pathogens that invade host cells by using a specialized apical complex and are usually transmitted by an invertebrate vector or intermediate host. In contrast to other Apicomplexans, Cryptosporidium is transmitted by ingestion of oocysts and completes its life cycle in a single host. No therapy is available, and control focuses on eliminating oocysts in water supplies 1 . Two species, C. hominis and C. parvum, which differ in host range, genotype and pathogenicity, are most relevant to humans [1] [2] [3] . C. hominis is restricted to humans, whereas letters to nature C. parvum also infects other mammals 2 . Here we describe the eight-chromosome ,9.2-million-base genome of C. hominis 2 . The complement of C. hominis protein-coding genes shows a striking concordance with the requirements imposed by the environmental niches the parasite inhabits. Energy metabolism is largely from glycolysis. Both aerobic and anaerobic metabolisms are available, the former requiring an alternative electron transport system in a simplified mitochondrion. Biosynthesis capabilities are limited, explaining an extensive array of transporters. Evidence of an apicoplast is absent, but genes associated with apical complex organelles are present. C. hominis and C. parvum exhibit very similar gene complements, and phenotypic differences between these parasites must be due to subtle sequence divergence.
We generated a ,12-fold sequence and ,8-fold bacterial artificial chromosome (BAC) clone coverage of the genome of C. hominis isolate TU502 (ref. 3 , Fig. 1, Supplementary Figs 1-8 , Supplementary Tables 1 and 2 ). Alignment of the ,9.2-million-base (Mb) final sequence with the HAPPY map 4 and chromosomes of the C. parvum genome 5 covered ,9.1 Mb. The eight chromosomes range from ,0.9 to ,1.4 Mb and exhibit 31.7% GC content (compare with 30.3% and 19.4% for C. parvum and P. falciparum 6 , respectively). The density of 2-50-base-pair (bp) repeats was about 1 per 2,800 bp. The distribution of repeats is biased towards chromosome ends because over 85% are in the telomere-proximal thirds of five of the chromosomes ( Supplementary Fig. 9 ). Two octamers, TGGCGCCA and TGCATGCA, over-represented in other apicomplexans 4 , are ,40-fold and 15-fold over-represented in C. hominis (Supplementary Table 3 ). More than 80% of these are in non-coding sequences, indicating possible regulatory or other conserved function. Fortyfive tRNAs, four or five rRNA operons-at least one of each of the two known types (Supplementary Table 4 )-and two clusters of three tandem 5S rRNA genes are present. As in P. falciparum 6 , two tRNA
Met genes are present, suggesting discrete roles in initiation and extension. We estimate that there are ,3,994 genes in C. hominis, in comparison with 3,952 genes in C. parvum and 5,268 in P. falciparum 6 (Table 1) . About 60% exhibit similarity to known genes. The distribution of GO annotations for Cryptosporidium, Plasmodium and Saccharomyces, is remarkably similar (Supplementary Fig. 10 ), indicating that their phenotypic differences are a reflection of non-conserved or previously unreported gene families of unknown function rather than to the functional specialization of conserved gene families. We estimate that 5-20% of C. hominis genes have introns.
Analysis of the C. hominis genome shows that the parasite possesses a highly tailored glycolysis-based metabolism, is dependent on the host for nutrients, and is exquisitely adapted for its life cycle (Fig. 2 , passing electrons from malate to an electron transport system composed of elements of Complexes I and III and an alternative oxidase system with O 2 as electron acceptor and producing no additional ATP.
Enzymes for metabolism of glycogen, starch and amylopectin are present, which is consistent with suggestions that amylopectin represents an energy reserve for sporozoites 10 . Lack of glucose-6-phosphate 1-dehydrogenase and other enzymes of the pentose phosphate pathway suggests that, unlike P. falciparum and other apicomplexans 6 , C. hominis cannot metabolize five-carbon sugars or nucleotides. Components of b-oxidation, for example enoylCoA hydratase and acetyl-CoA C-acyltransferase, are also absent, precluding ATP generation from fatty acids. Enzymes for the catabolism of proteins are also absent.
Major TCA-cycle enzymes-isocitrate dehydrogenase, succinylCoA synthase and succinate dehydrogenase-are absent in C. hominis. Despite the presence of ubiquinol-cytochrome c reductase, NADH dehydrogenase (ubiquinone), H þ -transporting ATPase and iron-sulphur cluster-like proteins, among others, key components of Complexes II and IV are absent, precluding ATP generation by oxidative phosphorylation. Components of oxidative phosphorylation that are present (parts of Complexes I and III) probably reoxidize NADH in a simplified electron-transport chain, letters to nature as in some plants and protozoa. Consistent with previous suggestions 11 is the observation that Cryptosporidium lacks enzymes for the synthesis of key biochemical building blocks-simple sugars, amino acids and nucleotides. However, starch, amylopectin and fatty acids can be generated from precursors. Interestingly, these C. hominis enzymes have minimal similarity to the known biosynthetic enzymes and are potential therapeutic targets.
Enzymes of the TCA, urea and nitrogen cycles and of the shikimate pathway are absent, indicating that Cryptosporidium is an amino-acid auxotroph. The shikimate pathway has been proposed as a potential target for glyphosate-based chemotherapy in other parasites including Cryptosporidium. We found no evidence to support this hypothesis. Enzymes that interconvert amino acids are encoded in C. hominis, and, unlike P. falciparum 6 , C. hominis has a large complement of amino acid transporters.
C. hominis lacks enzymes to synthesize bases or nucleosides, but encodes enzymes that convert nucleosides into nucleotides and letters to nature interconvert nucleotides. As in other parasites, thymidylate synthase and dihydrofolate reductase of C. hominis are encoded as a bifunctional polypeptide, and novel polymorphisms at crucial sites have been proposed to explain Cryptosporidium's resistance to antifolates 12 . As previously suggested 11 , several nucleotide conversion enzymes seem to have a prokaryotic origin.
Fatty-acid biosynthesis in apicomplexans occurs in the apicoplast by means of a type II system including fatty-acid synthase (FAS). However, consistent with the absence of an apicoplast in Cryptosporidium 13 is the observation that C. hominis encodes large FAS and polyketide synthase (PKS) enzymes, indicating a type I mechanism. The type I FAS and PKS enzymes of C. hominis also have prokaryotic characteristics 14, 15 . Glycerolipid and phospholipid metabolic pathways for phosphatidylinositol biosynthesis are available in C. hominis. 1,2-Diacylglycerol is a precursor for glycosylphosphatidylinositol anchor synthesis. All enzymes required for synthesis of these anchors are apparently present 16 .
Polyamines like putrescine, spermine and spermidine are critical for cellular viability, and enzymes required for their synthesis are attractive therapeutic targets. Cryptosporidium can synthesize polyamines using arginine decarboxylase rather than ornithine decarboxylase 17 . The putative arginine decarboxylase, spermidine synthase and other relevant enzymes encoded by C. hominis have diverged significantly from their homologues and are potential therapeutic targets.
C. hominis encodes adenylate cyclase, cyclic-AMP phosphodiesterase and protein kinase A, indicating the presence of the cAMPmediated signalling pathway (Supplementary Table 7) . Trimeric G protein, often involved in the activation of cAMP-mediated signalling, was not found in C. hominis, indicating that, as in Kinetoplastida 18 and reminiscent of plants, this pathway is independent of this complex in C. hominis. The presence of phosphatidylinositol 3-kinase and phospholipase C indicates that C. hominis utilizes phosphatidylinositol phosphate and Ca 2þ -mediated regulatory mechanisms. The presence of putative Ca 2þ transporters, Figure 2 Schematic representation of selective C. hominis proteins, enzymes and pathways. The green strip represents the cellular membrane with putative transporters; numbers indicate the number of genes for a given class of transporter. letters to nature enzymes associated with acidocalcisomes, and calmodulin imply that Ca 2þ transport and sequestering are functional. Protein kinase C receptors indicate that C. hominis has the ability to signal by activation of soluble cytoplasmic receptor-associated kinases.
No mitochondrial DNA sequences were found in C. hominis, and the TCA cycle and oxidative phosphorylation are absent (Supplementary Tables 5, 6 and 8) . However, a double-membrane-bound organelle generates a proton gradient using cardiolipin and performs some related mitochondrial functions, and mitochondrial marker chaperonin 60 was localized to this structure 19 . Core enzymes of [Fe-S] cluster biosynthesis, namely CpFd1, IscU, IscS, mt-HSP70, mtFNR and frataxin, have been reported in Cryptosporidium 20 , and we were not surprised to observe proteins involved in electron transport. We used CDART 21 to identify [Fe-S] domains in HscB (JAC) and ATM1, which are possibly involved in chaperonin activity of Hsp40/DnaJ type and ABC transport. Thus, C. hominis, like the microsporidian Encephalitozoon cuniculi 22 , another obligate intracellular parasite, contains a minimal set of these proteins. These results imply significant mitochondrial function in C. hominis and indicate that the previously reported organelle 19 is an atypical mitochondrion. Cryptosporidium apparently lacks an apicoplast 13, 23 , and searches of the C. hominis genome identified no apicoplast-encoded genes (Supplementary Table 9 ). Some putative nuclear-encoded apicoplast genes, for example acetyl-CoA carboxylase 1 precursor 24 and adenylyl cyclase 25 , are present. Others, such as the apicoplast 50S ribosomal protein L33 and the ribosomal L28 and S9 precursor proteins, were not found. The data indicate that Cryptosporidium lost an ancestral apicoplast. The presence of D-glucose-6-phosphate ketol-isomerase and 2-phospho-D-glycerate hydrolase, which are similar to plant genes and may be derived from ancient algal endosymbionts, is also indicative that engulfment of the alga that gave rise to the apicoplast preceded the divergence of Cryptosporidium from other apicomplexans. One hypothesis is that the acquisition of the type 1 FAS by a progenitor organism obviated the fatty-acid synthesis capabilities of the apicoplast 14, 15 . The C. hominis genome encodes multiple proteins specific for components of the apical complex including micronemes and rhoptries (Supplementary Table 9 ). No specific dense granuleassociated proteins were observed, probably because these proteins diverge rapidly 26 . However, proteins implicated in the regulation of transport and enhancement of the release of dense granule proteins 27 are present. As for Plasmodium, a typical Golgi structure is not apparent in C. hominis 23 . However, the presence of secretory organelles implies the existence of a functional endoplasmic reticulum and Golgi, and C. hominis encodes proteins similar to many related components, including the NSF/SNAP/SNARE/Rab machinery, which participates in dense granule release 28 , and the rhoptry biogenesis mediator activator protein 1, involved in endoplasmic-reticulum-Golgi-organelle protein traffic 29 . The endoplasmic-reticulum-Golgi-organelle machinery of C. hominis therefore seems similar to that of other apicomplexans.
As described above, C. hominis exhibits limited biosynthetic capabilities and is apparently dependent on its ability to import essential nutrients such as amino acids, nucleotides and simple sugars. The genome encodes more than 80 genes with strong similarity to known transporters and several hundred genes with transporter-like properties. At least 12 sugar or nucleotide-sugar transporters, five putative amino-acid transporters, three fattyacid transporters, 23 ABC family transporters including possible multiple-drug-resistance proteins, and several putative mitochondrial transporters are present. Other putative transporters for choline uptake, aminophospholipid transport, ATP/ADP, and others with unclear function, were also identified. These transporters are ideal therapeutic targets (Supplementary Table 10) .
Comparison of the genomes of C. hominis and C. parvum (Fig. 1,  Supplementary Table 11) showed that the two genomes are very similar, exhibiting only 3-5% sequence divergence with no large insertions, deletions ( Supplementary Fig. 11 ) or rearrangements evident. In fact, the gene complements of the two species are essentially identical because the few C. parvum genes not found in C. hominis are proximal to known sequence gaps (Supplementary Table 1 ). We therefore conclude that the significant phenotypic differences between these parasites are due to functionally significant polymorphisms in relevant protein-coding genes and to subtle gene regulatory differences.
A striking feature of the C. hominis genome is the concordance between its gene complement and the metabolic requirements in the environmental niches of its two primary life-cycle stages-the quiescent oocyst in the nutrient-poor aerobic environment of contaminated water, and the vegetative parasites in the nutrientrich anaerobic or microaerophilic environment of the host. Oocysts probably persist by aerobically metabolizing stores of complex carbohydrates by means of glycolysis and the alternative electron transport system in the unconventional mitochondrion. Consistent with the lack of the energy-generating TCA cycle, oxidative phosphorylation, b-oxidation and the pentose phosphate pathways is the observation that oocysts are relatively inactive, and the two ATP per glucose from glycolysis can provide sufficient energy. In the host, the parasite can import sugars to fuel glycolysis directly, netting two ATP per hexose. In limiting glucose, an additional two ATP per hexose can be generated either by converting acetyl-CoA to acetate or by means of glycerol metabolism. The residual mitochondrion lacks the TCA cycle and oxidative phosphorylation as expected in an organism that replicates in anaerobic or microaerophilic environments, and a simplified electron transport system for regenerating reducing power is available. Thus, a glycolysis-based metabolism is sufficient to support Cryptosporidium in all life-cycle stages.
As previously noted, our analysis shows that Cryptosporidium is a mosaic of sequences from diverse progenitors, including the hypothetical endosymbiont alga that formed the apicoplast, the mitochondrion and numerous genes acquired from prokaryotes by lateral transfer. Cryptosporidium also exhibits modular gene loss. We assume, on the basis of inference from other apicomplexans and earlier diverging groups such as the Euglenozoa, the Heterolobosea and the jakobids 30 , that Cryptosporidium progenitors exhibited the TCA cycle, b-oxidation, oxidative phosphorylation, amino acid, nucleotide and sugar biosynthesis, fully competent mitochondria, and a functional apicoplast. Genes associated with these functions are dispersed throughout the genome in Plasmodium and, we assume, in the progenitor. However, these systems seem to have been deleted cleanly in Cryptosporidium, leaving few identifiable residual genes or pseudogenes. Thus, the Cryptosporidium genome is a mosaic resulting from multiple lateral gene transfers and selective gene deletion.
The tailored physiology of C. hominis indicates attractive therapeutic targets (Supplementary Table 10 ), for example: essential transport systems; components of glycolysis; the unique prokaryotic FAS1 and PKS1; starch and amylopectin metabolism; nucleicacid or amino-acid metabolism; the AOX electron transport system; the bifunctional thymidylate synthase-dihydrofolate reductase; and the diverged polyamine synthesis enzymes. Finally, many potential vaccine targets were identified in the C. hominis genome (not shown), and, in contrast with other protozoan parasites, no extensive arrays of potentially variant surface proteins were observed, indicating a possible role for immunoprophylaxis for cryptosporidiosis.
The availability of the genome sequence of the human pathogen C. hominis is a crucial step forward in our understanding of the biology of this parasite. The gene complement provides very significant insight into its physiology and metabolism, validating previous hypotheses and indicating the possibility of others. New obvious targets for chemotherapy and immunotherapy are already apparent. In short, we expect that the availability of the sequence of C. hominis will stimulate progress in research on this organism and its pathogenicity, and strategies for intervention in the diseases it causes.
A
Methods
A modified whole-genome shotgun strategy was used to sequence the ,9.2-Mb genome of C. hominis isolate TU502, which was derived from an infected child from Uganda. DNA was purified from surface-sterilized oocysts, shotgun and BAC clones were constructed, and end sequences were generated. About 220,000 sequence reads from small insert clones, and end sequences from ,2,000 BAC clones averaging ,35 kbp in size, were generated. The data represents a ,12-fold shotgun clone coverage of the genome with a quality score of Phred 20, and a 7-8-fold coverage with BAC clones. The sequences were assembled with Phrap, yielding a ,9.16-Mb assembly, which was structurally and functionally analysed with a variety of available software programs and in-house scripts (see Supplementary Text 1 and 2 for further details and references).
Hepatocellular carcinoma is generally refractory to clinical treatment 1 . Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with rapid loss of expression of the tumour marker a-fetoprotein, the increase in expression of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver stem cell marker cytokeratin 19. Using in vivo bioluminescence imaging we found that many of these tumour cells remained dormant as long as MYC remain inactivated; however, MYC reactivation immediately restored their neoplastic features. Using array comparative genomic hybridization we confirmed that these dormant liver cells and the restored tumour retained the identical molecular signature and hence were clonally derived from the tumour cells. Our results show how oncogene inactivation may reverse tumorigenesis in the most clinically difficult cancers. Oncogene inactivation uncovers the pluripotent capacity of tumours to differentiate into normal cellular lineages and tissue structures, while retaining their latent potential to become cancerous, and hence existing in a state of tumour dormancy.
Cancer is largely caused by genomic catastrophes that result in the activation of proto-oncogenes and/or inactivation of tumoursuppressor genes 
